Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [(18)F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Corroyer-Dulmont, Aurélien, Pérès, Elodie A., Petit, Edwige, Guillamo, Jean-Sébastien, Varoqueaux, Nathalie, Roussel, Simon, Toutain, Jérôme, Divoux, Didier, MacKenzie, Eric T., Delamare, Jérôme, Ibazizène, Méziane, Lecocq, Myriam, Jacobs, Andréas H., Barré, Louisa, Bernaudin, Myriam, Valable, Samuel
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2013
Schlagworte:
Basic and Translational Investigations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3534417/
https://ncbi.nlm.nih.gov/pubmed/23115160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos260
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge